Sergio A. Giralt, MD

Articles

Dr. Giralt on the Potential Utility of Omidubicel in Hematologic Malignancies

March 16th 2021

Sergio A. Giralt, MD, discusses the potential utility of omidubicel in hematologic malignancies.

Dr. Giralt on Omidubicel Vs Standard Umbilical Cord Blood Transplant in Hematologic Malignancies

March 15th 2021

Sergio A. Giralt, MD, discusses the results of a phase 3 trial comparing omidubicel with standard umbilical cord blood transplant in hematologic malignancies.

Dr. Giralt on Current Standard of Care for Newly Diagnosed Multiple Myeloma

November 27th 2019

Sergio A. Giralt, MD, discusses the current frontline standard of care for patients with multiple myeloma.

Dr. Giralt on Evaluating MRD in Multiple Myeloma

November 15th 2019

Sergio A. Giralt, MD, professor of medicine at Weill Cornell Medical College, and chief, Adult Bone Marrow Transplant Service, Melvin Berlin Family Chair in Multiple Myeloma, at Memorial Sloan Kettering Cancer Center, discusses methods of evaluating measurable residual disease (MRD) in multiple myeloma.

Dr. Giralt on Transplant Eligibility Criteria in Multiple Myeloma

November 2nd 2019

Sergio A. Giralt, MD, professor of medicine at Weill Cornell Medical College, and chief, Adult Bone Marrow Transplant Service, Melvin Berlin Family Chair in Multiple Myeloma, at Memorial Sloan Kettering Cancer Center, discusses transplant eligibility criteria in multiple myeloma.

Dr. Giralt on Allogeneic HCT in Multiple Myeloma

February 23rd 2019

Sergio A. Giralt, MD, discusses the role of allogeneic hematopoietic cell therapy in patients with multiple myeloma.